{
    "id": 24387,
    "cites": 48,
    "cited_by": 0,
    "reference": [
        "Abrantes-Metz, Rosa M., Christopher P. Adams, and Albert Metz. 2004. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Pharmaceutical Development Phases: A Duration Analysis.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Federal Trade Commission, Bureau of Economics Working Paper Series, Working Paper No. 274.",
        "Aghion, Philippe, Richard Blundell, Rachel Griffith, Peter Howitt, and Susanne Prantl. 2009. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093The Effects of Entry on Incumbent Innovation and Productivity.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Review of Economics and Statistics, 91(1): 20\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c32.",
        "Arrow, Kenneth J. 1963. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Uncertainty and the Welfare Economics of Medical Care.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The American Economic Review, 53(5): 941\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c973.",
        "Baumol, William J., John C. Panzar, and Robert D. Willig. 1982. Contestable Markets and the Theory of Industrial Structure. New York:Harcourt Brace Jovanovich.",
        "Bennette, Caroline S., Catherine Richards, Sean D. Sullivan, and Scott D. Ramsey. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Steady Increase in Prices for Oral Anticancer Drugs After Market Launch Suggests a Lack of Competitive Pressure.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Health Affairs, 35(5): 805\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c812.",
        "Berndt, Ernst R., Rena M. Conti, and Stephen J. Murphy. 2017. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093The Landscape of US Generic Prescription Drug Markets, 2004-2016.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d NBER Working Paper Series, Working Paper No. 23640.",
        "Berndt, Ernst R., Thomas G. McGuire, and Joseph P. Newhouse. 2011. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d NBER Working Paper Series, Working Paper No. 16879.",
        "Berry, Steven T. 1992. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Estimation of a Model of Entry in the Airline Industry.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Econometrica, 60(4): 889\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c 917.",
        "Bhattacharya, Jayanta, and William B. Vogt. 2003. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093A Simple Model of Pharmaceutical Price Dynamics. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Journal of Law and Economics, 46(2): 599\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c626.",
        "Brekke, Kurt R., Chiara Canta, and Odd Rune Staume. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Reference pricing with endogenous generic entry.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of Health Economics, 50: 312\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c329.",
        "Bunch, David S., and Robert Smiley. 1992. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Who Deters Entry? Evidence on the Use of Strategic Entry Deterrents.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Review of Economics and Statistics, 74(3): 509\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c521.",
        "Capps, Cory, David Dranove, and Mark Satterthwaite. 2003. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Competition and market power in option demand markets.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d RAND Journal of Economics, 34(4): 737\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c763.",
        "Ching, Andrew T. 2010. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d International Economic Review, 51(4): 1175\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c1207.",
        "Claxton, Gary, Matthew Raw, Michelle Long, Anthony Damico, Bradley Sawyer, Gregory Foster, Heidi Whitmore, and Lindsey Schapiro. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Employer Health Benefits: 2016 Annual Survey.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Kaiser Family Foundaiton and Health Research and Educational Trust.",
        "Danzon, Patricia M., and Li-Wei Chao. 2000. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Does Regulation Drive Out Competition in Pharmaceutical Markets.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Journal of Law and Economics, 43(2): 311\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c358.",
        "DiMasi, J.A., L. Feldman, A. Seckler, and A. Wilson. 2010. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Trends in Risks Associated with New Drug Development: Success Rates for Investigational Drugs.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Clinical Pharmacology & Therapeutics, 87(3): 272\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c277.",
        "DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Innovation in the pharmaceutical industry: New estimates of R&D costs.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of Health Economics, 47: 20\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c33.",
        "Express Scripts. 2015. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093The 2015 drug trend report.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Food and Drug Administration. 2015. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093FDA approves Basaglar, the first \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093follow-on\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d insulin glargine product to treat diabetes.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d FDA Press Release.",
        "Frank, Richard G., and David S. Salkever. 1997. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Generic Entry and the Pricing of Pharmaceuticals.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Journal of Economics and Management Strategy, 6(1): 75\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c90.",
        "Gaynor, Martin, Carol Propper, and Stephan Seiler. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Free to Choose? Reform, choice, and consideration sets in the English National Health Service.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d American Economic Review, 106(11): 3521\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c 3557.",
        "Gaynor, Martin, Kate Ho, and Robert J. Town. 2015. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093The industrial organization of health-care markets.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of Economic Literature, 53(2): 235\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c284.",
        "Generic Pharmaceutical Association. 2015. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Generic Drug Savings in the US.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Geroski, P.A. 1995. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093What do we know about entry?\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d International Journal of Industrial Organization, 13: 421\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c440.",
        "Grabowski, Henry G., and John M. Vernon. 1992. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Journal of Law and Economics, 35(2): 331\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c350.",
        "Hay, Michael, David W. Thomas, John L. Craighead, Celia Economides, and Jesse Rosenthal. 2014. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Clinical development success rates for investigational drugs.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Nature Biotechnology, 32(1): 40\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c51.",
        "Ho, Katherine, and Robin S. Lee. 2017. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Equilibrium Provider Networks: Bargaining and Exclusion in Health Care Markets.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d NBER Working Paper No. 23742.",
        "Howard, David H., Peter B. Bach, Ernst R. Berndt, and Rena M. Conti. 2015. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Pricing in the Market for Anticancer Drugs.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of Economic Perspectives, 29(1): 139\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c162.",
        "Hua, Xinyang, Natalie Carvalho, Michelle Tew, Elbert S. Huang, William H. Herman, and Philip Clarke. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of American Medical Association, 315(13): 1400\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c1402.",
        "Kesselheim, Aaron S., Jerry Avorn, and Ameet Sarpatwari. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of American Medical Association, 316(8): 858\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c871.",
        "Kola, Ismail, and John Landis. 2004. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Can the pharmaceutical industry reduce attrition rates?\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Nature Reviews: Drug Discovery, 3: 711\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c715.",
        "Kyle, Margaret K. 2007. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Pharmaceutical Price Controls and Entry.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Review of Economics and Statistics, 89(1): 88\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c99.",
        "Lakdawalla, Darius, and Neeraj Sood. 2009. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Innovation and Welfare Effects of Public Drug Insurance.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of Public Economics, 91(1): 541\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c548.",
        "Lu, Z. John, and William S. Comanor. 1998. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Strategic Pricing of New Pharmaceuticals.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Review of Economics and Statistics.",
        "Mazzeo, Michael J. 2002. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Product choice and oligopoly market structure.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d RAND Journal of Economics, 33(2): 221\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c242.",
        "Morton, Fiona M. Scott. 1999. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Entry decisions in the generic pharmaceutical industry.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d RAND Journal of Economics, 30(3): 421\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c440.",
        "Nickell, Stephen J. 1996. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Competition and Corporate Performance.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Journal of Political Economy, 104(4): 724\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c746.",
        "Office of the Assistant Secretary for Planning and Evaluation. 2016. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093ASPE Issue Brief: Observations on Trends in Prescription Drug Spending.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Department of Health and Human Services.",
        "Pakes, Ariel, Michael Ostrovsky, and Steven Berry. 2007. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Simple estimators for the parameters of discrete dynamic games (with entry/exit examples).\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d RAND Journal of Economics, 38(2): 373\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c399.",
        "Perloff, Jeffrey M., Valerie Y Suslow, and Paul J. Seguin. 1995. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Higher Prices from Entry: Pricing of Brand-Name Drugs.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Working Paper: Competition Policy Center UC Berkley, WP Number CPC99-03.",
        "Powell, David. 2014. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Did the Economic Stimulus Payments of 2008 Reduce Labor Supply? Evidence from Quantile Panel Data Estimation.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d RAND Working Paper Series No. WR-710-3.",
        "Powell, David, and Joachim Wagner. 2014. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093The Exporter Productivity Premium along the Productivity Distribution: Evidence from Quantile Regression with Nonadditive Firm Fixed Effects.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Review of World Economics, 150(4).",
        "Reekie, W. Duncan. 1978. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Price and Quality Competition in the United States Drug Industry.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Journal of Industrial Economics, 26(3): 223\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c237.",
        "Reiffen, David, and Michael R. Ward. 2005. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Generic Drug Industry Dynamics.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Review of Economics and Statistics, 87(1): 37\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c49.",
        "Rothschild, Michael, and Joseph Stiglitz. 1976. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Equilibrium in Competitive Insurance Markets: An Essay on the Economics of Imperfect Information.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Quarterly Journal of Economics, 90(4): 629\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c649.",
        "Salop, Steven C. 1979. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Strategic Entry Deterrence.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d American Economic Review: Papers and Proceedings of the Ninety-First Annual Meeting of the American Economic Association, 69(2): 335\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c338.",
        "Santos, Rita, Hugh Gravelle, and Carol Propper. 2017. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Does Quality Affect Patients\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0084\u00a2 Choice of Doctor? Evidence from England.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d The Economic Journal, 127: 445\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c494.",
        "Selton, R. 1965. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Spieltheoretische Behandlung eines Oligopolmodells mit Nachfragetrgheit ? Teil I Bestimmung des dynamischen Preisgleichgewichts.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Zeitschrift fr die gesamte Staatswissenschaft, 121: 301\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c324.",
        "Tenn, Steven, and Brett W Wendling. 2014. \u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c5\u0093Entry Threats and Pricing in the Generic Drug Industry.\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00c2\u009d Review of Economics and Statistics, 96(2): 214\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c228.",
        "Tirole, Jean. 1988. The theory of industrial organization. MIT Press."
    ]
}